SCHEMBL4664437

SCHEMBL4664437

CCN(CC)c1ccc2nc3c4ccc(O)cc4c(=O)cc-3oc2c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.76
KMT2A Q03164 5/20 0.76
NPC1 O15118 1/20 0.76
POLB P06746 1/20 0.76
RAB9A P51151 1/20 0.76
SCP2 P22307 1/20 0.61
ALDH1A1 P00352 8/20 0.46
MAPT P10636 4/20 0.46
QPCT Q16769 1/20 0.44
GPR84 Q9NQS5 8/20 0.42
GLA P06280 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
HPGD P15428 3/20 0.42
CYP3A4 P08684 2/20 0.42
ATM Q13315 2/20 0.42
CASP1 P29466 2/20 0.42
CASP7 P55210 2/20 0.42
HSD17B10 Q99714 2/20 0.42
IGLV6-57 P01721 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL56792 0.96 MEN1 (0.76) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL16696324 0.88 MEN1 (0.61) MEN1KMT2ANPC1POLBRAB9A
Nile Red SCHEMBL49047 0.86 MEN1 (1.00) MEN1KMT2ANPC1POLBRAB9A
Nile Red SCHEMBL29373685 0.86 MEN1 (1.00) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL23733292 0.86 MEN1 (0.58) MEN1KMT2ANPC1POLBRAB9A
Nile Red SCHEMBL28703996 0.86 MEN1 (0.93) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL15398206 0.84 MEN1 (0.78) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL15398222 0.84 MEN1 (0.78) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL7815643 0.84 MEN1 (0.60) MEN1KMT2ANPC1POLBRAB9A
SCHEMBL23244667 0.83 MEN1 (0.70) MEN1KMT2ANPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210115000-A1 NILE RED DERIVATIVES FOR IMPROVED RATIOMETRIC IMAGING FOR NERVE SPECIFIC CONTRAST THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2021-04-22 US disclosed
US-20210115000-A1 NILE RED DERIVATIVES FOR IMPROVED RATIOMETRIC IMAGING FOR NERVE SPECIFIC CONTRAST THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2021-04-22 US disclosed
EP-2695930-B1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE, NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE DAINIPPON INK & CHEMICALS (JP) 2019-09-11 EP disclosed
US-9475991-B2 Polymerizable liquid crystal composition, polarized light-emitting coating material, novel naphtholactam derivative novel coumarin derivative, novel nile red derivative, and novel anthracene derivative ADEKA CORPORATION (JP) 2016-10-25 US disclosed
US-9475991-B2 Polymerizable liquid crystal composition, polarized light-emitting coating material, novel naphtholactam derivative novel coumarin derivative, novel nile red derivative, and novel anthracene derivative ADEKA CORPORATION (JP) 2016-10-25 US disclosed
EP-2695930-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE, NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE Adeka Corporation (JP) 2014-02-12 EP disclosed
US-20130334461-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE ADEKA CORPORATION (JP) 2013-12-19 US disclosed
US-20130334461-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, POLARIZED LIGHT-EMITTING COATING MATERIAL, NOVEL NAPHTHOLACTAM DERIVATIVE NOVEL COUMARIN DERIVATIVE, NOVEL NILE RED DERIVATIVE, AND NOVEL ANTHRACENE DERIVATIVE ADEKA CORPORATION (JP) 2013-12-19 US disclosed
US-20080038840-A1 Fluorescent Method And Compounds To Monitor Protein-Lipid Binding EUROPAEISCHES LABORATORIUM FUER MOLEKULARBIOLOGIE (DE) 2008-02-14 US disclosed
EP-1747207-A1 FLUORESCENT METHOD AND COMPOUNDS TO MONITOR PROTEIN-LIPID BINDING EUROPÄISCHES LABORATORIUM FÜR MOLEKULARBIOLOGIE (EMBL) (DE) 2007-01-31 EP disclosed
WO-2005113524-A1 FLUORESCENT METHOD AND COMPOUNDS TO MONITOR PROTEIN-LIPID BINDING Europäisches Laboratorium für Molekularbiologie (EMBL) (DE) 2005-12-01 WO disclosed
EP-1595872-A1 Fluorescent compounds for monitoring protein-lipid binding EUROPÄISCHES LABORATORIUM FÜR MOLEKULARBIOLOGIE (EMBL) (DE) 2005-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080038840-A1 Fluorescent Method And Compounds To Monitor Protein-Lipid Binding DBI, CETP, SREBF1 MEN1 3143/4885KMT2A 2814/4885NPC1 14/4885
US-20210115000-A1 NILE RED DERIVATIVES FOR IMPROVED RATIOMETRIC IMAGING FOR NERVE SPECIFIC CONTRAST FABP4, LRBA, FABP7 MEN1 3010/4885KMT2A 4468/4885NPC1 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.